The Molecular Biology of Myeloma
David S. Siegel, MD, PhD
Video Categories: Targeted Therapies
Dr. David S. Siegel discusses the importance of understanding the molecular biology of myeloma. Physicians can now look at and offer alternative treatments to patients that they identify will most likely do poorly with traditional treatment. He believes this area will develop quickly over the next 2 to 5 years.
As more oral oncolytics are developed, choosing the right regimen for prolonged disease-free survival presents a major patient management challenge. Dixie-Lee Esseltine, MD and George Mulligan, PhD explain that healthcare practitioners will have to make informed choices by balancing information emerging across similar trials.
Dr. Sanjiv Agarwala gives an overview of the roles dermatologists and medical oncologists play and expands on how and why they need to work together to improve cancer care.